Active, not recruitingNCT04011722

Portico Next Generation Approval Study

Abbott Medical DevicesMultiple US sitesView on ClinicalTrials.gov

AI Description

The purpose of this clinical study is to evaluate the acute safety and effectiveness of the next-generation Navitor (Portico™ NG) Transcatheter Aortic Heart Valve as assessed by the rate of all-cause mortality at 30 days and the rate of moderate or greater paravalvular leak at 30 days in a high or extreme surgical risk patient population to support CE (Conformité Européenne) Mark and FDA approval.

Report inaccurate information

Who can join
adult, older adult
Participants
333
Expected completion
2033-01
Funded by
industry

Conditions studied

Symptomatic Severe Aortic Stenosis

What is being tested

  • DEVICE: Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery System
  • DEVICE: Portico™ NG (Navitor) Valve and FlexNav™ Delivery System

What it measures

  • Primary Effectiveness Endpoint is Moderate or Greater Paravalvular Leak, Number of participants with moderate or greater paravalvular leak at 30 days., at 30 days
  • Primary Safety Endpoint is All-cause Mortality, All-cause mortality is defined as the total number of deaths in each cohort at 30 days., at 30 days

Centers Participating

These centers are participating in this study. Reach out to them directly to learn more.

Data Sources and Methodology

Registry entry updated 2026-07-21

Deciding whether to join a study is your choice, and you can ask a study team questions before you decide anything.

If you would rather we did it with you, call us on (656) 206-4686.